Epoxyazadiradione

SKU HY-N10096-1 mg Category Tags , ,

$130$520

Products Details

Product Description

– Epoxyazadiradione is a limonoid purified from neem (Azadirachta indica) fruits. Epoxyazadiradione inhibits the tautomerase activity of MIF of both human (huMIF) and malaria parasites (Plasmodium falciparum (PfMIF) and Plasmodium yoelii (PyMIF)) non-competitively in a reversible fashion (Ki, 2.11-5.23 μM). Epoxyazadiradione has the potential against proinflammatory reactions induced by MIF of both malaria parasites and human[1].

Web ID

– HY-N10096

Storage Temperature

– -20°C, 3 years; 4°C, 2 years (Powder)

Shipping

– Room Temperature

Applications

– COVID-19-immunoregulation

Molecular Formula

– C28H34O6

References

– [1]Alam A, et al. Novel anti-inflammatory activity of epoxyazadiradione against macrophage migration inhibitory factor: inhibition of tautomerase and proinflammatory activities of macrophage migration inhibitory factor. J Biol Chem. 2012;287(29):24844-24861.

CAS Number

– 18385-59-6

Molecular Weight

– 466.57

Compound Purity

– 99.21

SMILES

– C[C@]12[C@]34[C@]([C@@](C5=COC=C5)([H])C([C@@]3([H])O4)=O)(CC[C@]1([H])[C@@]6([C@@](C(C)(C(C=C6)=O)C)([H])C[C@H]2OC(C)=O)C)C

Clinical Information

– No Development Reported

Research Area

– Infection

Solubility

– 10 mM in DMSO

Target

– Parasite

Isoform

– Plasmodium

Pathway

– Anti-infection

Product type

– Natural Products

Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

=

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.

=